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Major Depressive Disorder (MDD) is the leading cause of disability worldwide. 
The prevalence of MDD is 12% in men and 20% in women. Antidepressant drugs are the 
first line of treatment in Major Depressive Disorder and other mood disorders, 
particularly selective-serotonin reuptake inhibitors. Affective blunting is a potential side 
effect of chronic SSRI treatment, which can be defined as a diminished response to 
pleasurable or unpleasant stimuli, and is indicated as a marked indifference towards 
engagement in activities. The present study looked to examine the effects of chornic 
fluoxetine (0.16g/L) administration on pre-test and post-test performance of a light 
aversion task and a sucrose preference test. The light aversion task presents subjects with 
a bright aversive light which can be terminated by a head-entry into an apparatus, and are 
measured as escape responses. The sucrose preference test measures amount of sucrose 
consumption pre and post treatment. A significance was found in the male fluoxetine 
group, who performed significantly less escape responses than before treatment.  There 
were no significant differences between treatment groups found in female operant 
responding, nor in the sucrose preference test. This study is the first known attempt to 
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Major Depressive Disorder (MDD) is characterized by five or more of the 
following symptoms: depressed mood, noticeable diminished interest in activities once 
found enjoyable, significant bodyweight changes (5% of body weight within one month), 
insomnia or hypersomnia, psychomotor agitation, daily fatigue, excessive ill-suited guilt, 
diminished ability of concentration, and/or reoccurring thoughts of death. These 
symptoms of depression must cause clinically impaired functioning in social or 
occupational areas of life (American Psychiatric Association, 2013). Clinically, 
depression can have multiple dimensions, and the DSM-5 classifies these as specifiers. 
For example, an individual with major depressive disorder with “anxious distress” 
indicates that the individual experiences anxiety-related symptoms as well  (American 
Psychiatric Association, 2013).  
Major depressive disorder is ranked as the leading cause of disability worldwide 
by the World Health Organization (2018). According to the Centers for Disease Control 
and Prevention, nearly 3% of Americans aged 12 and older have had severe depressive 
symptoms, 4.7% have had moderate symptoms, and 15.3% have had mild symptoms. The 
prevalence of chronic major depressive disorder in the United States is 12% in men and 
20% in women (Belmaker & Agam 2008). Greenberg et al. (2015) estimated the 
economic burden of depression to be $210.5 billion in 2010, which has grown from $53 
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billion in 2003 (Wang, Simon, & Kessler, 2003). The suicide rate in depressed patients is 
10-15%, and 60-70% of patients with depression have suicidal ideation (Möller 2003).  
 Treatments for depression can include psychotherapeutic interventions and 
pharmacological treatments. Cognitive behavioral therapy is the most widely used 
psychotherapeutic approach to treating mental disorders (Forman, Herbert, Moitra, 
Yeomans, & Geller, 2007). While cognitive behavioral therapy is the most commonly 
studied for psychotherapy, this may have led to over estimation of its effectiveness 
(Cuijpers, Berking, Anderson, Quigley Kleiboer, & Dobson, 2013). Antidepressant drug 
use has increased from 6.8% of the population (1999-2000) to 13% of the population 
(2011-2012). Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) and Selective 
Serotonin Reuptake Inhibitor (SSRI) treatments have been key in facilitating the growth 
of antidepressant drug use. SNRI use increased from 0.4% (1999-2000) to 2.0% (2011-
2012), and SSRI use increased from 4.3% (1999-2000) to 8.5% (2011-2012) (Kantor, 
Rehm, Haas, Chan, & Giovannucci, 2015).  Möller (2003) conducted a meta-analysis that 
reported the most common and effective treatment for major depressive disorder, as well 
as depressed mood and anxiety disorders, is antidepressant drug therapy.  
Neurobiology of depression 
The neuropathology of depression is complex and studies have found both 
structural changes and differences in structural activity in patients with major depressive 
disorder. Drevets et al. (1997) conducted a study that used positron emission tomography 
to assess cerebral blood flow and glucose metabolism to measure brain activity in 
depressed patients. They found decreased activity in the subgenual area of the prefrontal 
cortex. Coinciding with these findings, a study using magnetic resonance imaging (MRI) 
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found the volume of this structure reduced in patients with major depressive disorder 
(Drevets et al., 1997). 
 The nucleus accumbens also appears to be affected among patients with 
depression. The nucleus accumbens regulates reward and motivation, an aspect that is 
often referred to as an inability to respond to hedonic stimuli (Berlin et al., 1998). 
Schlaepfer et al. (2008) conducted a study using deep brain stimulation in the nucleus 
accumbens for treatment-resistant depression in three individuals. The researchers found 
that after only 60-s of stimulation of the nucleus accumbens, patients exhibited an 
immediate interest in doing novel activities or engaging in activities they once enjoyed 
doing.  
Increased resting blood flow in the amygdala, a structure important for fear and 
aggression, appears in depressed individuals (Drevets et al., 1992; Gotlib & Joormann, 
2010). Drevets et al. (1992) conducted a PET assessment showing decreased activity in 
the left amygdala. Later studies by the same research group concluded that glucose 
uptake is also increased in the left amygdala in those with depression, implying greater 
activity in this area (Drevets, Bogers, & Raichle, 2002).  
Becker et al. (2007) has proposed that a vital function of the hippocampus is to 
apply negative-feedback control over the hypothalamic-pituitary-adrenal axis, which is 
responsible for the body’s stress response. Another function the hippocampus is to exert 
negative-feedback to the amygdala, nucleus accumbens, and medial prefrontal cortex, 
which are structures responsible for motivation and emotion processing. Malberg, Eisch, 
Nestler, and Duman (2000) examined the effects of antidepressant drug treatment on 
hippocampal neurogenesis in the adult male rat. Their study tested three different 
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antidepressant drugs (fluoxetine [SSRI], reboxetine [norepinephrine reuptake inhibitor], 
and tranylcypromine [monoamine oxidase inhibitor, MAOI]) against saline, as well as a 
negative control (haloperidol [typical antipsychotic drug]). Negative controls in 
psychopharmacology are treatments in which either no response or response in the 
opposite direction of the experimental hypothesis is expected. Results from this 
experiment showed that antidepressant drug treatment caused increased proliferation of 
cells in the dentate gyrus of the hippocampus, whereas haloperidol did not show an 
increase in proliferation. Whether or not these new cells mature at an accelerated rate was 
inconclusive, however, evidence suggests that fluoxetine does increase the maturation of 
these new cells.  
Wang, David, Monckton, Battaglia, and Hen (2008) studied whether or not 
chronic fluoxetine administration to rats would have an influence on maturation of new 
hippocampal granule cells. The authors found that chronic fluoxetine administration 
resulted in doublecortin-positive immature neurons displaying an increase in dendritic 
branching. Coinciding with this finding, there was a significant increase of mature neuron 
markers found after chronic fluoxetine administration. These findings suggest that 
antidepressants not only promote neurogenesis, but also increase the likelihood of those 
cells maturing.  The importance of antidepressant drugs having an influence on 
hippocampal cell maturation is due to the hippocampus’ role in emotional memory. The 
hippocampus has abilities to associate episodic memory with aversive or positive 
emotions by communication with the amygdala, which is responsible for informing us if 
a situation is dangerous or pleasant.  
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 Much of the support for the neurochemistry in the neuropathology of depression 
comes from pharmacological effects of antidepressant drugs (see below). One of the 
earliest theories of depression is the Monoamine-Deficiency Hypothesis. This hypothesis 
suggests depression is due to diminished levels of monoamine neurotransmitters, given 
that antidepressant drugs increase monoamine neurotransmitter levels.  
Antidepressant Drugs 
The discovery of antidepressant drug therapy occurred by accident. In the 1950’s, 
the drug iproniazid was developed for the purpose of treating tuberculosis. In 1952, 
studies were taking place to assess the clinical effects of iproniazid, specifically at the 
Sea View Hospital of Staten Island. Patients undergoing this treatment showed an all-
around increased feeling in energy, as well as greater interest in being social. Clinicians 
reported that despite the physical ailments associated with tuberculosis, patients were 
actually dancing in the hallways with one and other. The energy that patients were 
experiencing was so grand, that the staff believed the patients were well enough to leave 
the hospital. Despite the attempts to brand iproniazid as a psychiatric treatment, it would 
only ever be marketed as a tuberculosis treatment (López-Muñoz & Alamo 2009).  
The accidental findings of iproniazid’s antidepressant effects led to the first class 
of antidepressant treatment, known as MAOIs. MAOIs bind to monoamine oxidase 
(MAO) enzymes in the body, preventing the breakdown of monoamine neurotransmitters 
(i.e., dopamine, norepinephrine, and serotonin.). It was unknown that MAOIs would 
elevate levels of tyramine, which would otherwise be metabolized by MAO. Tyramine is 
often produced by foods that are primarily aged or fermented (this includes cheese and 
alcohol). The effect of tyramine during MAOI treatment can cause increased blood 
 
 6 
pressure that is so high, it could be lethal. This interaction is commonly known as the 
Cheese Effect (Mc-Cabe-Sellers, Staggs, & Bogle, 2006). 
Although the first MAOIs were not well tolerated by patients, they led the way 
toward research and development for other antidepressant drugs. Tricyclic 
antidepressants (TCAs) were the next antidepressants introduced after MAOIs, which 
was discovered in 1955, as an experimental antidepressant compound (Brown & 
Rodolsky, 2015). TCAs block the reuptake of norepinephrine and serotonin (Lennox & 
Frazer, 2002). These treatments tended to also not be tolerated well by patients due 
largely to anticholinergic side effects, such as dry mouth, constipation, blurred vision, 
confusion, and delirium. One of the most common side effect of TCAs is sedation, due to 
the anticholinergic and antihistaminergic effects (Zajecka & Tummala, 2002). It is also 
worth noting that TCAs slow cardiac conduction, and their cardiotoxicity is so high that a 
fatal overdose can occur with 1 week worth of medication (Khawam, Laurencic, & 
Malone 2006).  
The newer classes of antidepressant drugs are SSRIs, SNRIs, and norepinephrine-
dopamine reuptake inhibitors (NDRIs, e.g., bupropion). SSRIs act upon inhibiting the 
reuptake of serotonin, while SNRIs inhibit the reuptake of serotonin and norepinephrine. 
Blocking reuptake of these neurotransmitters means there will be an increased amount of 
serotonin and/or norepinephrine in the synaptic cleft. NDRIs inhibit the reuptake of 
norepinephrine and dopamine (Ascher et al., 1995).  
 Antidepressant drug therapy is the leading treatment for depressed mood, major 
depressive disorder, and anxiety disorders. SSRIs are the most common types of 
antidepressant drugs prescribed, due to their tolerability by patients (Opbroek et al., 
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2002). However, the delay in the onset of antidepressant effects can last from two to six 
weeks. They also have side effects specifically linked to inhibition of serotonin reuptake. 
Weight gain and sexual dysfunction are some of the more common side effects a patient 
might experience when beginning treatment with an antidepressant that elevates serotonin 
levels (Demyttenaere & Jaspers 2008). These effects usually subside within a few weeks 
of continuing treatment, however conjunctive therapy is an increasingly more common 
area to treat these effects.   Commonly used conjunctive therapy includes the addition of 
the NDRI bupropion. A more severe side effect that may take place, especially with a 
sudden increase in dose, is the serotonin syndrome (Birmes et al., 2003). The serotonin 
syndrome consists of physical ailments such as increased body temperature and tremor, 
which could result in death if treatment continued, and mental ailments such as agitation 
(Boyer & Shannon, 2005).  
 Abruptly ceasing SSRI treatment can lead to the serotonin discontinuation 
syndrome. Certain symptoms associated with discontinuation syndrome are not specific 
to SSRI discontinuation, but can also present following discontinued use of any 
antidepressant drug that includes significant inhibition of serotonin reuptake as a 
mechanism of action, such as tricyclic antidepressant drugs or SNRIs. These symptoms 
include nausea, headache, insomnia, akathisia (movement disorder), behavior resembling 
mania, dizziness, and vertigo (Schatzberg et al., 1997). Another symptom of serotonin 
discontinuation syndrome comes in the form of sensory abnormalities. Specifically, 
patients have described the feeling of an electric “shock-like” sensation or a “jolt.” This 
feeling occurs in up to 5% of SSRI patients who abruptly discontinue use (Frost et al., 
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1995). The serotonin discontinuation syndrome can be prevented by tapering off the 
doses of the medication (Black et al, 2000). 
Affective Blunting 
While SSRIs are effective for attenuating depressive and anxious symptoms, use 
of these treatments could result in a side effect known as affective blunting. Affective 
blunting can be defined as a diminished response to pleasurable or unpleasant 
stimuli.  Hoen-Saric et al. (1990) gathered case studies of patients treated with SSRIs 
who reported a lack of engagement in activities that they were once interested in. 
Indifference toward engagement ranged from not caring about paying utility bills to 
losing interest in their professional work.  
While these observations were noted in patients treated with SSRIs, some 
elements appear similar to symptoms found in depression. The DSM-5 reports one 
symptom of depression being diminished interest and/or pleasure in almost all activities, 
which contributes to the difficulty in establishing a definition for affective blunting. 
While this is a defined symptom in the DSM-5 (American Psychiatric Association, 2013), 
individuals diagnosed with depression also exhibit extreme emotional responding. For 
example, those diagnosed with depression often exhibit greater irritability that presents as 
an exaggerated frustration response over seemingly minor incidents (American 
Psychiatric Association, 2013).  
The DSM-5 focuses on the reduction of engagement in pleasurable activities, yet 
does not include diminished responding to aversive situations. The inability to be 
substantially affected by negative situations seems to be due to prolonged SSRI 
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treatment. For instance, patients report an inability to cry in situations where this 
response would be appropriate (Price et al., 2009; Opbroek et al., 2002).  
Opbroek et al., (2002) conducted a study to quantify emotional blunting 
symptoms in individuals diagnosed with depression who were being treated with SSRI 
antidepressant drugs. Five subjects each were treated with either fluoxetine, paroxetine, 
or sertraline. All of the individuals diagnosed with depression were determined to be in 
remission following the criteria of the Hamilton Depression Rating Scale (HAMD), to 
ensure that their feelings could not be attributed to depression. A control group was 
composed of hospital employees where the participants were chosen from, these 
employees had never been diagnosed with Major Depressive Disorder. The authors of 
this study designed a psychometric measurement named the Laukes Emotional Intensity 
Scale (LEIS) (Opbroek et al., 2002). This assessment consists of 18 emotional states: (1) 
ability to cry, (2) feel motivated, (3) feel irritated or upset, (4) interest in sex, (5) care 
about others feelings, (6) feel sadness, (7) have erotic dreams, (8) enjoy eating, (9) feel 
energetic, (10) have creativity, (11) feel surprise, (12) become angry, (13) expression of 
feelings, (14) pleasure during sex, (15) feel joy, (16) involved and interest in work, (17) 
experience worry, and (18) feel assertive.  
The results of this study showed that individuals undergoing SSRI treatment 
showed emotional blunting in the following items: 1-7, 10-14, and 17. Total mean scores 
for LEIS in the treatment group of participants were shown to be statistically lower than 
for controls. One limitation that Opbroek et al. (2002) found is that those individuals 
chosen for this treatment group had previously been involved in a study measuring the 
relationship between SSRI treatment and sexual dysfunction. Also, the number of 
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subjects in this study were small (N=15). Regardless of these limitations, this empirical 
evidence gives a direction for further research in larger studies. It would be helpful to 
also include other antidepressant drug treatments, such as SNRIs and NDRIs  
Price, Cole, and Goodwin (2009) conducted a qualitative study of individual, 
group and validation interviews, to better understand emotional blunting in individuals on 
SSRI treatment. The blunting of emotions was broken down into eight categories in this 
experiment: “general emotional affect,” “reduction of positive emotions,” “reduction of 
negative emotions,” “emotional detachment,” “just not caring,” “changed personality,” 
and “effects on everyday life.” Almost all patients conveyed emotions as being 
‘flattened’ or ‘numbed,’ for some patients even completely ‘blocked.’ Most individuals 
reported a reduction in both positive and negative emotions. While reduction in 
emotional distress is often seen as beneficial for depression, lacking enjoyment of social 
situations or loved hobbies is a potential limitation to treatment. Many participants 
attributed reduced motivation to their SSRI medication.  These authors concluded that all 
emotional effects were attributed to, in whole or in part, the patient’s antidepressant 
medication.  
One theory of depression is the emotional-context insensitivity hypothesis, which 
proposes that depressed individuals have a weakened response to positive and negative 
environmental stimuli, which can be characterized as blunted affect (Carlson et al., 2017). 
Grillon et al., (2013) claim, however, that major depressive disorder (MDD) is not 
supported by the emotional-context insensitivity hypothesis. The authors conducted a 
startle reflex experiment where the MDD group showed high levels of startle while 
anticipating shock, when compared with a control group. Therefore, the participants with 
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MDD were capable of exhibiting a strong negative response. Patients have noted their 
lack of drive was unlike that of sedation or previous depressive episodes (Hoen-Saric et 
al., 1990; Opbroek et al., 2002).  
Despite affective blunting’s uniqueness, there appears to be a need to examine 
this effect closer, and displays a need for representation in animals. Due to the limited 
research in affective blunting as a potential side effect of antidepressant drug use it needs 
to be thoroughly examined in animal models before they move on to clinical trials. 
Animal models for screening antidepressant drugs 
The forced swim test (behavioral despair model) and tail suspension test are two 
animal models of depression used for screening antidepressant drug efficacy. Forced 
swim test is conducted by placing a rat or mouse in a beaker of water, and then measuring 
time of immobility and latency of immobility. Antidepressant drugs decrease immobility 
and latency of immobility in this model.  Tail suspension infers a similar interpretation as 
forced swim, in the form of mobility, except mice are suspended by their tail for several 
minutes. Petit-Demouliere et al. (2005) conducted a study comparing an SSRI and SNRI 
using the tail suspension paradigm. The authors found that both fluoxetine and 
venlafaxine reduced the amount of immobility in mice, but fluoxetine produces less of an 
effect than venlafaxine.  
 Another model for depression in animals is learned helplessness. A learned 
helplessness task will typically involve a group of animals presented with inescapable 
shock since the start of training, against another group given escapable shock since the 
start of training. Motivation can be observed when being presented with inescapable trials 
of shock. For example, Hannum et al. (1989) conducted a study with rats presented with 
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inescapable shock since being weaned, against a group of rats presented with no shock or 
escapable shock. The authors found that when all rats were later presented with 
conditions of escapable shock, rats with inescapable shock since being weaned failed to 
escape the shock even if it were escapable. Failing to escape a shock can be described as 
failure to move throughout the shuttle box to an area without shock or failing to press a 
lever that terminates the shock. Seligman & Groves (1970) conducted a study that 
revealed emotional deficits present with inescapable shock. After one session of 
inescapable shock, rats failed to escape escapable shock after 5 minutes, 1 hour, 24 hours, 
and 168 hours. Takamori et al. (2002) did a similar study testing three different 
antidepressants; imipramine (tricyclic), tranylcypromine (monoamine-oxidase inhibitor), 
and fluvoxamine (selective serotonin reuptake inhibitor) and dopamine receptor agonists; 
SKF38393 (D1 receptor agonist), quinpirole (D2 receptor agonist), and 7-OH-DPAT (D3 
receptor agonist), using the learned helplessness paradigm. Measuring escape failures 
consists of the times the subject does not move to the part of the shuttle box where shock 
is not being applied to the grid floor.  All three antidepressants tested reduced number of 
escape failures, and so did the D1 and D2 receptor agonists, but not the D3 receptor agonist.  
It is possible to study levels of motivation in laboratory animals. A common 
representation of anhedonia, or the inability to engage in pleasurable activities, is the 
sucrose preference test. The sucrose preference test presents subjects with a choice 
between sucrose solution or tap water. It is expected that an animal will drink from the 
sucrose water as opposed to tap water, the reason being is that sucrose has added reward 
compared to plain tap water (Rygula et al., 2005). Sucrose preference can be reduced by 
chronic mild stress (CMS), which involves alteration to housing conditions (e.g. tilted 
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cage, soiled bedding, new house mates). Willner et al. (1987) concluded that tricyclic 
antidepressant treatment could reverse the effects that chronic mild stress had on sucrose 
preference. Muscrat, Papp, and Willner (1992) found that the tricyclic antidepressant 
maprotiline and the SSRI fluoxetine could reverse the effects of chronic mild stress 
induced lack of sucrose preference. Sucrose, employed as a rewarding stimulus, can be 
measured by consumption before and after chronic antidepressant treatment to see if 
preference has changed. Lack of engagement will be displayed as a lack of preference 
between sucrose water and tap water.  
Animal models for screening side effects of SSRIs  
While many animal models of depression are available, there are few animal 
behavioral models for examining antidepressant side effects. A study conducted by 
Cantor, Binik and Pfaus (1998) evaluated the sexual behavior of male rats chronically 
treated with fluoxetine and their interaction with receptive females. The greatest deficits 
appeared as decreased appetitive sexual behavior and decreased ejaculation frequency. 
Another study, this time using female rats, was done to measure how fluoxetine disrupts 
the estrous cycle (Uphouse, Hensler, Sarkar, and Grossie, 2006).  These authors 
concluded that the estrous cycle was lengthened and progesterone blood levels were 
decreased with fluoxetine treatment. However, continuing administration of fluoxetine 
past 17 days did appear to regulate sexual behavior in these female rats. Both studies also 
reported reduced body weight in rats treated with fluoxetine. Uphouse et al. (2006) even 
added a pair-fed aspect to their study, conveying that appetitive disruption on fluoxetine 




Effect of female estrous cycle on learning and memory 
Behavioral studies of rats tend to use males due to their amount of reliability in 
behavioral operant procedures. One of the reasons males are often utilized over females is 
due to the variability in learning and memory at different phases of the female estrous 
cycle. Female rats have an estrous cycle that last approximately 3-5 days on average. 
During this time the female rat will go through four phases: proestrus, estrus, metestrus, 
and diestrus (Miland et al., 2009; Warren & Juraska, 1997). Throughout the estrous cycle, 
female rats will have morphological and electrophysiological changes (Warren & 
Juraska, 1997) which are due to their fluctuating hormone levels. During proestrus 
females will produce higher levels of estrogen and progesterone while during metestrus 
and estrus phases females will produce lower levels of estrogen and progesterone (Miland 
et al., 2009).  
 Warren & Juraska (1997) conducted a study to determine if female rat cycle 
would have an effect on spatial memory in the Morris water maze (MWM). The MWM 
procedure administers cues which enable the rodent to navigate the perimeter of an open 
swimming arena, where they are to locate a submerged escape platform (Vorhees & 
Williams, 2006). Warren & Juraska (1997) found that females during their estrus phase 
(low levels of estrogen and progesterone) performed better than females during their 
proestrus phase, suggesting that females perform better spatially during the estrus phase 
of their cycle. Further, Miland et al. (2009) went on to measure whether or not the female 
rat estrus cycle had an effect on performance in a fear conditioning task – particularly 
fear extinction. The authors found that female rats in their metestrus phase (low estrogen 
and progesterone) exhibited significantly greater amounts of freezing when compared to 
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the group of females in their proestrus phase. The results of both of these studies suggest 
that the time during a female’s estrus cycle may significantly impact their abilities to 
respond during behavioral tasks. 
Rationale 
Depression is often viewed as a disruption in emotional processing, however, 
from reviewing a multitude of studies examining the emotional side effects associated 
with SSRI treatment, it appears depression and emotional side effects are not the same. 
Patients have repeatedly communicated a reduction in both positive and negative 
emotions, following SSRI treatment. To date, few studies have examined an association 
between antidepressant treatment and affective blunting. Studies that have been 
conducted were limited to surveying the prevalence and severity of affective blunting, 
and there have yet to be studies aimed at exploring neuropharmacologic mechanisms 
mediating these effects. Females were utilized in the present study to represent the large 
amount of female human population who undergo antidepressant drug treatment. 
Including them here, is representative of modeling the human population., 
 The present study is a first step toward evaluating the link between SSRI 
treatment and affective blunting by attempting to model these effects in laboratory rats. 
We plan to observe the effects of chronic fluoxetine administration on motivation to 
engage in positive stimuli and avoid aversive stimuli. Fluoxetine was chosen due to its 
common prevalence when treating depressive symptoms, along with its high association 
with emotionally aversive side effects. The sucrose preference test was used as a measure 
of the amount of effort animals will devote to a rewarding activity and a light aversion 
test was designed to measure the effort dedicated to escaping  aversive conditions. It was 
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hypothesized that animals treated with fluoxetine will engage less in the sucrose 
preference test, consuming less sucrose than the control group. Next, it was hypothesized 
that animals treated with fluoxetine will emit less escape responses after chronic 
treatment. It was hypothesized that animals treated with fluoxetine will emit greater 
omission responses after treatment. Hypothesis four proposed that fluoxetine treated 
animals will emit less premature responses after treatment. Finally, hypothesis five 
proposed that fluoxetine treated animals will have a longer latency average following 
chronic administration.  All tests were conducted before and after 21 days of fluoxetine 
administration. The development of animal behavior models capable of displaying 
affective blunting-like effects following antidepressant treatment will allow for extensive 
follow up investigations into the mechanisms mediating these effects along with a 




















Thirty-eight Wistar rats (19 males and 19 females; Crl: WI strain; purchased from 
Charles River Laboratories) weighing 250g-300g were used for this study. Housing and 
experimental procedures took place in the Neuropsychopharmacology Laboratory at 
Northern Michigan University. Animals were boarded separately in a vivarium with a 
constant temperature and humidity. A 12 h light/dark cycle was programmed for the 
vivarium. Experimental procedures were conducted during the dark cycle. The 
procedures were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals and approved by the Institutional Animal Care and Use Committee 
(IACUC) at Northern Michigan University.  
Drugs 
Fluoxetine was a gift from the  NIMH Chemical Synthesis and Drug Supply 
Program (Bethesda, MD). Fluoxetine was administered in home cage water bottles in an 
amount of 0.16g/L (expressed as salt form of the drug). The water bottles were wrapped 
in aluminum foil to avoid break down of the drug by light. The dose selected for this 
study was based on Li et al. (2012).  
Apparatus 
Sucrose Preference Task.  
 Two water bottles, specific for rodents, were used during the sucrose preference 
task. The lids attached to the water bottles were equipped with a stainless steel ball at the 
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end to ensure no liquid was lost for accurate measurement of consumption. All water 
bottles were covered in aluminum foil and duct tape to avoid novelty, as this is how the 
fluoxetine bottles appeared.  
Light Aversion Operant Task. 
Operant chambers specific for rats (Med-Associates Inc., St. Albans, VT) were 
used. Chambers were equipped with a aperture with a photo beam sensor, a fan for 
ventilation and masking noise. The aperture was positioned 60 mm above the chamber 
grid floor (Figure 1). The aperture was 40 mm in diameter and 30 mm in length. The 
photobeam sensors were positioned 15 mm inside of the aperture, and a beam break was 
recorded only after a continual interruption of at least 1 second. The top of the chamber 
consisted of a single transparent Plexiglas panel. A 12 watt LED bulb (equivalent to 100 
watt incandescent bulbs) was positioned approximately 2 cm above the chamber top, 
centered over the chamber. The equipment was controlled by and data gathered by 
MedPC IV for Windows (Med-Associates Inc.).  
 




Light aversion training. 
Each training session consisted of 40 trials, and the session length was 20 
minutes. The experiment examined escapes by recording the frequency of head entries 
and latency of head entry from the time of light activation. Escapes were defined, in this 
experiment, as head entries passing the photo beams for a duration of at least 1s. A bright 
light (1130 lumens) was used as an aversive stimulus during the sessions.  
For escape behavior, the bright light was delivered  for a duration of 30-s, unless 
terminated by an escape response (head entry into response aperture). Termination of the 
light by an escape response was succeeded by a 20-s period of darkness. Otherwise, the 
light was terminated after the 30-s duration and only 5-s period of the light off occurred. 
Data were categorized as escape responses, omissions, premature responses, response 
latency average, and total responses.  
 Rats were treated with either fluoxetine or vehicle for 21 days. Determination of 
which rats received fluoxetine and which received vehicle were randomly assigned.  Two 
procedures took place – sucrose preference test and light aversion task (Figure 1). 
Animals were tested and trained prior to fluoxetine administration and tested again after 
21 days of administration. Following this, a washout period of two weeks given, and 
testing was conducted 7 days (day 29) and 14 days (day 36) after the completion of 
fluoxetine administration.  
Experiment 1: Sucrose Preference Test. 
During the execution of this test, animals were presented with two water bottles – 
one with a 1% sucrose solution (Willner et al. 1987) and the other with tap water in 
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standard housing cages. After 12 hours, the bottles were switched to avoid side 
preference (Rygula et al. 2005).  
Before fluoxetine administration. 
For a period 72 hours before the sucrose preference test, the home cage water 
bottles were filled with a 1% sucrose solution to acclimate rats to the sucrose water 
(Bushnell et al., 1988; Li, Y., Pehrson, A. L., Budac, D. P., Sánchez, C., & Gulinello, M., 
2012). On the day following this 72-hour period, two water bottles were wrapped in 
aluminum foil and added to the home cages.  One of the bottles contained a 1% sucrose 
solution and the other contained tap water. Water bottles were weighed before and after 
the 24-hour test session to determine sucrose and water consumption. 
After fluoxetine administration.  
On the final day of fluoxetine administration, fluoxetine was provided in two 
water bottles placed in the home cage (or tap water for the fluoxetine control group). On 
the next day, a sucrose preference test was conducted as described previously. After that, 
both sucrose and fluoxetine were removed from home cages and testing was conducted 
for light intensity motivation. Subsequent sucrose preference testing was conducted on 
day 29 and day 36, after cessation of fluoxetine administration.   
Experiment 2: Effects of light motivation on escape rates.  
Test sessions that took place following fluoxetine treatment consisted of 20 trials, 
and the session length was reduced, from 20 minute training session, to 10 minutes. Test 





Data Analysis.  
Sucrose consumption (based on water bottle weights), operant escape responses, 
response omissions, premature responses, total responses, and response latencies served 
as dependent variables in this study, and data were calculated as a percentage of baseline 
and reported as means (+/- the standard error of the mean). Percent of baseline was 
calculated by dividing the post-test value from the baseline value and multiplied by 100. 
A fluoxetine group and a fluoxetine-vehicle group (non-treatment control) was assigned 
for both male and female rats. Two-way, mixed factors analysis of variance (ANOVA) 
tests were conducted within each sex across time and between treatment conditions for 
each variable. Bonferroni post-hoc comparisons were used following statistically 
significant ANOVA results. Unpaired t-tests were conducted to calculated differences in 
body weight between treatment groups. Additionally, an unpaired t-test was calculated to 
determine difference in fluoxetine consumption between female and male subjects. 















Figure 2, middle panel, represents the mean amount of fluoxetine consumption 
over the course of the 21 day treatment. The mean fluoxetine consumption per day for 
females (M = 19.94, SD = 1.770) was lower than mean fluoxetine consumption per day 
for males (M = 24.97, SD = 2.023). 
 
Figure 2. Mean amount of fluoxetine water consumed by treatment group, water 
containing 0.16g/L of fluoxetine 
Body Weights 
Mean weight for females is displayed in figure 3, left panel. Weight change in 
females is displayed in figure 4, right panel. In females, there was a significant difference 
found in weight change before and after treatment between the fluoxetine group (M = 
10.44, SD = 10.24) and control group (M = -5.30, SD = 5.846); t(17) = 4.05, p < 0.001. 
Females in the fluoxetine group gained weight throughout the experiment while females 
in the vehicle group lost weight. Mean weights for males is displayed in figure 5, left 

















panel. Weight change in males is displayed in figure 6, right panel. There was no 
significant difference found in males for weight change before and after treatment 
between the fluoxetine group (M = -19.08, SD = 20.60) and the control group (M = -
17.66, SD = 19.02); t (17) = 0.1560, p > 0.05. Signifying both groups of male subjects 
lost weight throughout the experiment. This was due to male rats completely consuming 
their daily allotted amount of food. 
  
Figure 3. Shows the pre vs. post treatment   Figure 4. Shows the pre and post  
mean weights for female subjects.  mean weight change for female. 
 
  
Figure 5. Shows the pre vs. post treatment  Figure 6. Shows the pre and post  


























































































Sucrose Preference Test 
The mean percentage of sucrose consumption during the sucrose preference test 
for females is shown in figure 7, left panel. There was not a statistically significant 
difference found between treatments (F [1, 17] = 0.322, p > 0.05). However, there was a 
significant difference found across test days (F [3, 51] = 27.87, p < 0.0001). An increase 
of sucrose consumption was found for fluoxetine treated females at day 22, day 29, and 
day 36, when compared to baseline consumption. Similarly, females in the control group 
showed an increase in sucrose consumption on day 22 and day 36 when compared to 
baseline, but not day 29. The mean percentage of sucrose consumption for sucrose 
preference test in males is shown in figure 8, right panel. A statistically significant 
difference was not found between treatments (F [1, 17] = 5.381, p > 0.05). Similarly to 
females, there was a significant difference found across test days for males (F [3, 51] = 
13.03, p < 0.0001). There was an increase of sucrose consumption for fluoxetine treated 
males at day 22, day 29, and day 36, compared to baseline. Additionally, male rats 
receiving vehicle showed an increase in sucrose consumption at 22, when compared to 
baseline.  
 
Figure 7. Shows the mean percentage of Figure 8. Shows the mean percentage of 
sucrose consumption for females on each sucrose consumption for males on each  
test day.      test day.   
 







Sucrose Preference Test - Female





























Sucrose Preference Test - Male

























Light Aversion Operant Task  
 For the light aversion operant task, all females that completed training 
(n=19), met the criteria after 20.89 (+/- SEM = 0.3749) sessions. One of the female rats 
was removed from the study after repeatedly failing to emit responses in the chamber (the 
rat instead spent the sessions chewing on the response aperture). All males (n = 19) met 
the training criteria after mean of 19.26 (+/- SEM = 0.3749) daily training sessions. The 
difference in sessions to training criteria between the male and female rats was 
statistically different, t (7) = 4.337, p < 0.001. 
The mean percentage of baseline for escape responses for females in the light 
aversion task is shown in figure 9, left panel. A statistically significant difference was 
neither found across test days (F [3, 48) = 1.300, p = 0.2852) nor between treatments (F 
[1,16] = 0.001, p = 0.9713). There were no interaction effects present in female escape 
behavior when comparing day 0 and day 22 (F [3,48] = 0.5512, p = 0.8487).  Male mean 
percentage of baseline for escape responses for in the light aversion task is shown in 
figure 10, right panel. A statistically significant difference was neither found across test 
days (F [3, 51] =1.218, p = 0.3126) nor between treatments (F [1, 17] = 0.365, p = 
0.5538). However, there was a statistically significant interaction effect in males, (F [3, 
51] = 3.061, p = 0.0359). A significant decrease in escape responses was found at day 22 








Figure 9. Shows the percentage of baseline Figure 10. Shows the percentage of baseline 
as a mean of escape responses in females.  as a mean of escape responses in males.  
 
The mean percentage of baseline for omission responses for females in the light 
aversion task is shown in figure 11, left panel. A statistically significant difference was 
neither found across test days (F [3, 38] = 2.487, p = 0.0717) nor between treatments (F 
[1, 16] = 0.455, p = 0.5094). There were no interaction effects found in female omission 
responses (F [3,48] = 0.3012, p = 0.8244). Figure 12, right panel, displays the mean 
percentage of baseline for omissions responses for males in the light aversion task. There 
was not a statistically significant difference found across test days (F [3, 51] = 0.524, p = 
0.1038) nor between treatments (F [3,17] = 0.148, p = 0.7054). There were no interaction 
effects found in male omission responses (F [3,51] = 0.5239, p = 0.6678). 
 
Figure 11. Shows the percentage of   Figure 12. Shows the percentage of  
baseline as means of omission responses baseline as means of omission responses  
in females     in males.  
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The mean percentage of baseline for premature responses for females in the light 
aversion task is displayed in figure 13, left panel. A statistically significant difference 
was neither found across test days (F [3, 48] = 1.954, p = 0.5501) nor between treatments 
(F [1,16] = 0.880, p = 0.3620). Females did not display any interaction effects for 
premature responses (F [3,48] = 1.954, p = 0.1335). The mean percentage of baseline for 
premature responses for males in the light aversion task is shown in figure 14, right 
panel. Again, there was not a statistically significant difference found across test days (F 
[3, 51] = 1.077, p = 0.3673) or between treatments (F [1, 17] = 1.285, p = 0.2727). There 
were no interaction effects found for male premature responses (F [3,51] = 1.236, p = 
0.3061). 
 
Figure 13. Shows the percentage of   Figure 14. Shows the percentage of  
baseline as means of premature   baseline as means of premature  
responses in females.    responses in males. 
 
Figure 15, left panel, represents the mean percentage of baseline for latency 
average for females in the light aversion task. There was not a statistically significant 
difference found across test days (F [3, 48] = 0.661, p = 0.5796) nor between treatments 
(F [1, 16] = 0.002, p = 0.9624). There were no interaction effects found for female 
latency averages (F [3,48] = 0.5297, p = 0.6641). The mean percentage of baseline for 
latency average for males in the light aversion task is shown in figure 16, right panel. 
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Premature Responses - Male















However, a statistically significant difference was neither found across test days (F [3, 
51] =1.417, p = 0.2484) nor between treatments (F [1, 17] = 2.153, p = 0.1605). Males 
did not display any interaction effects for latency average, either (F [3,51] = 0.4863, p = 
0.6933).    
The non-normative data for female latency averages is represented in figure 17, 
left panel. Females did not display a significant difference across test days (F [3,48] = 
0.4428 p = 0.7234) nor between treatments (F [1,16] = 1.513, p = 0.2365). There were no 
significant interaction effects found for non-normative latency averages, either (F [3,48] 
= 0.9503, p = 0.4238). The non-normative data for male latency averages is displayed in 
figure 18, right panel. There were no significant differences found for males across test 
days (F [3,51] = 1.717, p = 0.1752) nor between treatment groups (F [1,17] = 0.5415, p = 
0.4718). Additionally, there were no significant interaction effects present for male non-
normative latency averages (F [3,51] = 0.2768, p = 0.8419).  
 
Figure 15. Shows the percentage of   Figure 16. Shows the percentage of  
baseline as means of latency average  baseline as means of latency average 
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Latency Average - Male

















Figure 17. Shows the non-normative   Figure 18. Shows the non-normative 
means of latency average in females.   means of latency average in males.  
 
The mean percentage of baseline for total responses for the females in the light 
aversion task is shown in figure 19, left panel. There was not a statistically significant 
difference found across test days (F [3, 48] = 1.042, p = 0.3826) nor between treatments 
(F [1, 16] = 0.130, p = 0.7231). Females did not display any interaction effects for total 
responses (F [3,48] = 0.6591,  p = 0.5814). Figure 20, right panel, represents the mean 
percentage of baseline for total responses for the males in the light avoidance task. Again, 
a statistically significant difference was neither found across test days (F [3, 51] = 0.954, 
p = 0.4214) nor between treatments (F [1, 17] = 1.417, p = 0.2503). Similarly, there were 
no interaction effects present for male total responses (F [3,51] = 1.043, p = 0.3814). 
 
 
Figure 19. Shows the percentage of   Figure 20. Shows the percentage of  
baseline as means of total responses   baseline as means of total responses 
in females     in males.  
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The measures utilized  in this study have shown reliability in examining 
rewarding and aversive behavior in rats. Implementing a sucrose preference test was to 
determine if fluoxetine had an effect on whether or not animals would still engage in a 
rewarding stimulus (Li et al., 2012). The present study determined that fluoxetine 
administration does not have an effect on sucrose consumption in rats, however this is 
inconclusive. A different variation of acclimation may display other findings. The light 
aversion operant task was used in the present research, as bright light has been 
determined to be an aversive measure in albino rats (Barker et al., 2010). The present 
study displayed significance in only one operant measure, escape responses. Males 
treated with fluoxetine emitted significantly less amounts of escape behaviors when 
compared to their male control group. Both female and male sex were used in the present 
study to represent the human population that is likely to be given SSRI treatment. 
Body Weights 
As previously stated, SSRI treatment typically causes weight fluctuation with the 
onset of treatment (Demyttenaere & Jaspers 2008). In this present study, significant 
weight changes were found in the female fluoxetine group, when compared to those 
receiving vehicle treatment. This is consistent with findings in human clinical studies 
(Uher et al., 2011). However, in regards to the male sample in this present study, there 
was a significant change in pre/post weights. These weight changes were observed for 
both fluoxetine treated males and vehicle treated males. The change in weight for males 
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can be attributed to their overconsumption of food before fluoxetine administration. 
While males were not put on food-deprivation, they were consuming all of their food by 
the next morning of feeding was given. Some male rats were reaching 600g before 
fluoxetine treatment began, which is considered overweight for Wistar rats. 
Sucrose Preference Test 
The inclusion of the sucrose preference test was to determine if rats would engage 
in a rewarding stimulus after chronic fluoxetine administration. While it was 
hypothesized that rats who were treated with fluoxetine would have lower sucrose 
consumption than that of the control group, the results indicated that there was no 
significant difference. This was true for sex of the rats as well; neither male or female had 
a significant change in sucrose consumption. A possible explanation for not seeing any 
significant effect in the sucrose preference test could be due to fluoxetine not affecting 
motivation for this type of reinforcer. Future studies might consider using additional 
SSRI’s when using this test along with incorporating other types of reinforcers.     
 The results of this study are inconsistent with other findings on fluoxetine 
treatment utilizing a sucrose preference test.  Brenes & Fornaguera  (2009) conducted an 
experiment with the effects of social isolation and sucrose preference. Sucrose 
consumption initially increased with social isolation. However, when a group was treated 
with fluoxetine their sucrose consumption reduced significantly. This group of 
researchers did use a different concentration of sucrose water (32%), and accumulated 
data over a 48-hour time period, in contrast to the present study utilizing a 72-hour 
acclimation period and a 24-hour test period (Brenes & Fornaguera, 2009).  
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One reason that we failed to see a difference in sucrose consumption could be due 
to the timeline of the sucrose preference test in relation to the beginning of fluoxetine 
treatment. While other studies have shown that a 72-hour acclimation period was 
sufficient (Li et al., 2012), it is possible that the 72-hour sucrose acclimation period was 
too close to the sucrose preference test and subsequently the onset of fluoxetine 
administration. However, Li et al. (2012), followed a differing protocol for a saccharin 
preference test. Animals in the present study were given 72-hours of acclimation, while 
Li et al (2012) gradually increase saccharin concentration from day 1 (0.025%) to day 2 
(0.1%) and were then water-deprived for day 3 of acclimation. Present studies involving 
sucrose preference would benefit from having a water-deprived 24-hours directly prior to 
the 24-hour test session. 
Light Aversion Operant Task  
The purpose of this study was to determine if rats who are treated with fluoxetine 
would respond differently to stimuli than rats who were not treated 
pharmacologically.  The hypothesis proposed that rats treated with fluoxetine would 
engage less in the light aversion task when compared to the control group. A lessened 
engagement in escaping an the aversive light, can be translated to a human who doesn’t 
care to escape situations where they may be affected negatively. There was no significant 
difference when sex was ignored in any of the operant tasks performed.  However, there 
was a significant difference between male rats treated with fluoxetine and male control 
rats in one of the operant measures. Male rats treated with fluoxetine for 21 days 
exhibited significantly lower amounts of escape behavior when compared to the control 
group. This is supportive of the hypothesis that fluoxetine treatment lessens the 
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engagement in escaping a negative stimulus, which is  representative as a blunted affect 
in rodents. Bright lights are shown to be an aversive stimulus in rodents (Barker et al., 
2010). Barker and colleagues expanded on this by determining rats would also avoid 
bright light, by burrowing before the light was triggered, which should be a next step in 
studying affective blunting as well. The results of prior studies have shown that 
behavioral tasks in rodents have been reliable in translating to human behavior (Neumann 
et al., 2011).   
An increased number of omission responses would be an illustration of affective 
blunting in rats, as greater omission responses would translate to not caring to terminate 
the bright light. The present study hypothesized that omission responses would increase 
after 21 days of fluoxetine administration, which we failed to see. While the graph does 
appear to show an increase at day 22 when compared to day 0, its significance did not 
meet cut-off criteria for females (p = 0.0717) or males (p = 0.1038). 
Future Directions 
Twenty days of training might not have been sufficient in establishing clear 
learning behavior of the light aversion operant task. However, Barker et al (2010) were 
able to establish significance in only 10 sessions of escape behavior. On average, each rat 
participated in 20 training days. Training was established if the escape responding 
behavior did not vary beyond the standard deviation of the last 5 days of training. Pre-test 
data indicates that females performed escape behavior at 60.57% (fluoxetine group) and 
60.22% (control group) of their baseline measures and males performed escape behavior 
57-64% of their baseline measures. Subsequently, the omission responses were accounted 
for in 48.91% (fluoxetine group) and 57.44% (control group) of the time in females, 
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while males performed at 49.20% (fluoxetine group) and 45.75% (control group) of 
baseline omission responses during pre-test. It is possible that using a longer time frame 
of training would show increased escape response reliability. Another variable to 
consider would be frequency of training. 
Future studies in this area may consider adding various light intensities to their 
testing paradigm, which was also suggested by Barker et al (2010). The benefit of 
different light intensities added to the light aversion operant task may display a change in 
responding when a weak aversive stimuli is presented versus a strong aversive stimuli. In 
turn, this may correlate to the amount of aversive stimuli a human may be more apt avoid 
while experiencing affective blunting.  
Expanding this research onto other affective measures such as social isolation 
would prove beneficial in the area of affective blunting. Case studies that were previously 
mentioned report that individuals display an indifferent affect in emotional engagement 
with family and/or peers (Price et al., 2009; Hoen-Saric et al., 1999). Brenes and 
colleagues (2008) who conducted a study with chronic fluoxetine administration did so 
while rodents were being reared. Further research with fluoxetine on adult rodents and 
their social isolation may prove to be beneficial when moving forward with animal 
models of affective blunting. 
The benefit of utilizing additional species of animals in antidepressant drug 
treatment is due to the fact that different species can offer unique perspectives into 
behavioral representation. For example, different mice strains can respond differently to 
one experiment such as effects of inescapable foot shock (Yan et al., 2010). Additionally, 
the forced swim test paradigm is displayed differently in rodents and mice as well. The 
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forced swim test can be effective in using mice within one exposure to their water, while 
rats demonstrate the need to learn the task prior to testing (Yan et al., 2010). A next step 
to be taken after rodent research, for affective blunting, would be the development of 
nonhuman primate models. The benefit of utilizing nonhuman primates is due to their 
increased similarity to human functioning (Phillips et al., 2014). Nonhuman primates 
demonstrate complex behavior in environmental and social which are similar to humans. 
Pharmacological treatment studies on primates can also mirror case studies that are often 





















While significance was only seen in escape behavior for male rats treated with 
fluoxetine, longer periods of training may result in significance found in the other operant 
measures (i.e., omission response, premature response,  total response, and latency 
average). As previously mentioned, female percentage of baseline for omissions were 
nearing significance following fluoxetine treatment (p = 0.0717) and changes to their 
training criteria may display a significant increase in blunted affect in the form of an 
omission response. Female rats may benefit from a longer training period due to their 
estrous cycles, to display clear learning behavior. Females could also benefit from 
additional testing days during their estrous cycle to see if it indeed has an effect on their 
ability to respond. Another way to control for the female rat estrous cycle would be 
utilizing ovariectomized rats, this would eliminate the need for monitoring which phase 
of the cycle they were experiencing. The purpose of including females in this study is to 
represent the large amount of female human population that is likely to be put on SSRI 
treatment following diagnosis of a mood disorder such as Major Depressive Disorder, 
and few studies typically utilize females. Future research  in this area should look to 
include females in their studies, as well.  
Further research should look to include other SSRIs, a wider range of treatment 
doses, and additional time courses of SSRI treatment. Applying this area of research to 
other species (e.g., mice) would prove to be beneficial, as well. The assessment measures 
of this research could also be expanded on. Implementing affective measures such as 
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social interaction, mild stress, and/or ultrasonic vocalizations should be the next direction 
taken in the research of affective blunting. This study is the first known attempt to model 
affective blunting induced by chronic SSRI use in animals. The results from this research 
give indication of which areas should be expanded on as future research progresses in this 






















American Psychiatric Association. (2013). Diagnostic and statistical manual of mental  
disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.  
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., ... &  
 Richelson, E. (1995). Bupropion: a review of its mechanism of antidepressant  
 activity. The Journal of clinical psychiatry. 
Barker, D. J., Sanabria, F., Lasswell, A., Thrailkill, E. A., Pawlak, A. P., & Killeen, P. R.  
(2010). Brief light as a practical aversive stimulus for the albino rat. Behavioural  
brain research, 214(2), 402-408. 
Becker, S., & Wojtowicz, J. M. (2007). A model of hippocampal neurogenesis in  
memory and mood disorders. Trends in cognitive sciences, 11(2), 70-76. 
Belmaker, R. H., & Agam, G. (2008). Major depressive disorder. New England Journal  
of Medicine, 358(1), 55-68. 
Berlin, I., Givry-Steiner, L., Lecrubier, Y., & Puech, A. J. (1998). Measures of anhedonia  
and hedonic responses to sucrose in depressive and schizophrenic patients in  
comparison with healthy subjects. European Psychiatry, 13(6), 303-309. 
Birmes, P., Coppin, D., Schmitt, L., & Lauque, D. (2003). Serotonin syndrome: a brief  
review. Cmaj, 168(11), 1439-1442. 
Black, K., Shea, C., Dursun, S., & Kutcher, S. (2000). Selective serotonin reuptake  
inhibitor discontinuation syndrome: proposed diagnostic criteria. Journal of  
Psychiatry and Neuroscience, 25(3), 255. 
Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. New England Journal of  
 Medicine, 352(11), 1112-1120. 
 
 39 
Brenes, J. C., & Fornaguera, J. (2009). The effect of chronic fluoxetine on social  
isolation-induced changes on sucrose consumption, immobility behavior, and on  
serotonin and dopamine function in hippocampus and ventral  
striatum. Behavioural brain research, 198(1), 199-205. 
Brown, W. A., & Rosdolsky, M. (2015). The clinical discovery of  
imipramine. American  Journal of Psychiatry, 172(5), 426-429. 
Bushnell, P. J., & Peele, D. B. (1988). Conditioned flavor aversion induced by inhaled p- 
xylene in rats. Neurotoxicology and teratology, 10(3), 273-277. 
Cantor, J. M., Binik, Y. M., & Pfaus, J. G. (1999). Chronic fluoxetine inhibits sexual  
behavior in the male rat: reversal with oxytocin. Psychopharmacology, 144(4), 
355-362. 
Cuijpers, P., Berking, M., Andersson, G., Quigley, L., Kleiboer, A., & Dobson, K. S.  
(2013). A meta-analysis of cognitive-behavioural therapy for adult depression,  
alone and in comparison, with other treatments. The Canadian Journal of  
Psychiatry, 58(7), 376-385. 
Depression. (2018, March 22). Retrieved June 5, 2019, from https://www.who.int/news- 
room.fact-sheets/detail/depression 
Drevets, W. C., Price, J. L., Simpson Jr, J. R., Todd, R. D., Reich, T., Vannier, M., &  
Raichle, M. E. (1997). Subgenual prefrontal cortex abnormalities in mood  
disorders. Nature, 386(6627), 824. 
Drevets, W. C., Videen, T. O., Price, J. L., Preskorn, S. H., Carmichael, S. T., & Raichle,  
M. E. (1992). A functional anatomical study of unipolar depression. Journal of  
Neuroscience, 12(9), 3628-3641. 
 
 40 
Drevets, W. C., Bogers, W., & Raichle, M. E. (2002). Functional anatomical correlates of  
antidepressant drug treatment assessed using PET measures of regional glucose  
metabolism. European Neuropsychopharmacology, 12(6), 527-544. 
Frost, L., & Lal, S. (1995). Shock-like sensations after discontinuation of selective  
serotonin reuptake inhibitors. The American journal of psychiatry. 
Gotlib, I. H., & Joormann, J. (2010). Cognition and depression: current status and future  
 directions. Annual review of clinical psychology, 6, 285-312. 
Greenberg, P. E., Fournier, A. A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015). The  
economic burden of adults with major depressive disorder in the United States 
(2005 and 2010). The Journal of clinical psychiatry, 76(2), 155-162. 
Grillon, C., Franco-Chaves, J. A., Mateus, C. F., Ionescu, D. F., & Zarate, C. A. (2013).  
Major depression is not associated with blunting of aversive responses; evidence  
for enhanced anxious anticipation. PloS one, 8(8), e70969. 
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004). Discovering 
 endophenotypes for major depression. Neuropsychopharmacology, 29(10), 1765. 
Hoehn-Saric, R., Lipsey, J. R., & McLeod, D. R. (1990). Apathy and indifference in  
patients on fluvoxamine and fluoxetine. Journal of clinical psychopharmacology. 
Forman, E. M., Herbert, J. D., Moitra, E., Yeomans, P. D., & Geller, P. A. (2007). A 
randomized controlled effectiveness trial of acceptance and commitment therapy 
and cognitive therapy for anxiety and depression. Behavior modification, 31(6), 
772-799. 
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015).  
 
 41 
Trends in prescription drug use among adults in the United States from 1999-
2012. Jama, 314(17), 1818-1830. 
Kessler, R. C. (2012). The costs of depression. The psychiatric Clinics of north  
America, 35(1), 1. 
Khawam, E. A., Laurencic, G., & Malone, D. A. (2006). Side effects of antidepressants:  
an overview. Cleveland Clinic Journal of Medicine, 73(4), 351-353.  
Lenox, R. H., & Frazer, A. (2002). Mechanism of action of antidepressants and mood  
stablizers.  In Neuropsychopharmacology: the fifth generation of progress.  
Philadelphia: Lippincott Williams & Wilkins. 
Li, Y., Pehrson, A. L., Budac, D. P., Sánchez, C., & Gulinello, M. (2012). A rodent  
model of premenstrual dysphoria: progesterone withdrawal induces depression- 
like behavior that is differentially sensitive to classes of  
antidepressants. Behavioural brain research, 234(2), 238-247.  
López-Muñoz, F., & Alamo, C. (2009). Monoaminergic neurotransmission: the history of  
the discovery of antidepressants from 1950s until today. Current pharmaceutical  
design, 15(14), 1563-1586. 
Mann, J. J. (2003). Neurobiology of suicidal behaviour. Nature Reviews  
Neuroscience, 4(10), 819. 
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000). Chronic antidepressant   
treatment increases neurogenesis in adult rat hippocampus. Journal of  
Neuroscience, 20(24), 9104-9110. 
Martin, P., Soubrie, P., & Simon, P. (1987). The effect of monoamine oxidase 
inhibitors compared with classical tricyclic antidepressants on learned 
 
 42 
helplessness paradigm. Progress in Neuro-Psychopharmacology and Biological 
Psychiatry, 11(1), 1-  7. 
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C.,  
... & Kennedy, S. H. (2005). Deep brain stimulation for treatment-resistant  
 depression. Neuron, 45(5), 651-660. 
McCabe-Sellers, B. J., Staggs, C. G., & Bogle, M. L. (2006). Tyramine in foods and  
monoamine oxidase inhibitor drugs: a crossroad where medicine, nutrition,  
pharmacy, and food industry converge. Journal of Food Composition and  
Analysis, 19, S58-S65. 
Milad, M. R., Igoe, S. A., Lebron-Milad, K., & Novales, J. E. (2009). Estrous cycle phase  
and gonadal hormones influence conditioned fear  
extinction. Neuroscience, 164(3), 887-895. 
Mitchell, A. J., & Dening, T. R. (1996). Depression-related cognitive impairment:  
possibilities or its pharmacological treatment. Journal of affective  
disorders, 36(3), 79-87. 
Möller, H. J. (2003). Suicide, suicidality and suicide prevention in affective  
disorders. Acta Psychiatrica Scandinavica, 108(s418), 73-80. 
Murray, C. J., & Lopez, A. D. (1996). Global burden of disease (Vol. 1, pp. 118-201).  
Boston: Harvard University Press. 
Muscat, R., Papp, M., & Willner, P. (1992). Reversal of stress-induced anhedonia by the  
atypical antidepressants, fluoxetine and  
maprotiline. Psychopharmacology, 109(4), 433-438. 
Neumann, I. D., Wegener, G., Homberg, J. R., Cohen, H., Slattery, D. A., Zohar, J., ... &  
 
 43 
Mathé, A. A. (2011). Animal models of depression and anxiety: What do they tell  
us about human condition?. Progress in Neuro-Psychopharmacology and  
Biological Psychiatry, 35(6), 1357-1375.  
Olfson, M., Marcus, S. C., Druss, B., Elinson, L., Tanielian, T., & Pincus, H. A. (2002).  
National trends in the outpatient treatment of depression. Jama, 287(2), 203-209. 
Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., &  
Manber, R. (2002). Emotional blunting associated with SSRI-induced sexual  
dysfunction. Do SSRIs inhibit emotional responses?. International Journal of  
Neuropsychopharmacology, 5(2), 147-151. 
Phillips, K. A., Bales, K. L., Capitanio, J. P., Conley, A., Czoty, P. W., ‘t Hart, B. A., ...  
& Nathanielsz, P. W. (2014). Why primate models matter. American journal of  
primatology, 76(9), 801-827. 
Price, J., Cole, V., & Goodwin, G. M. (2009). Emotional side-effects of selective  
serotonin reuptake inhibitors: qualitative study. The British Journal of  
Psychiatry, 195(3), 211-217. 
Rihmer Z, Akiskal HS. Do antidepressants t(h)reat(en) depressives? Toward a clinically  
judicious formulation of the antidepressant-suicidality FDA advisory in light of  
declining  national suicide statistics from many countries. J Affect Disord 2006; 
94:3–13. 
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998).  
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized  
clinical trial. Biological psychiatry, 44(2), 77-87. 
Rygula, R., Abumaria, N., Flügge, G., Fuchs, E., Rüther, E., & Havemann-Reinecke, U.  
 
 44 
(2005). Anhedonia and motivational deficits in rats: impact of chronic social  
stress. Behavioural brain research, 162(1), 127-134. 
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., ... & Belzung, C.  
(2003). Requirement of hippocampal neurogenesis for the behavioral effects of  
antidepressants. science, 301(5634), 805-809. 
Schlaepfer, T. E., Cohen, M. X., Frick, C., Kosel, M., Brodesser, D., Axmacher, N., ... &  
Sturm,  V. (2008). Deep brain stimulation to reward circuitry alleviates anhedonia 
in refractory major depression. Neuropsychopharmacology, 33(2), 368-377. 
Schatzberg, A. F., Haddad, P., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young,  
A. H., & Zajecka, J. (1997). Serotonin reuptake inhibitor discontinuation  
syndrome: a hypothetical definition. The Journal of clinical psychiatry. 
 
Scoville, W. B., & Milner, B., (1957). Loss of Recent Memory After Bilateral  
Hippocampal   Lesions. Journal of Neurology, Neurosurgery & Psychiatry, 20(1),  
11-21.  
Sherman, A.D., Petty, F. (1982) Additivity of neurochemical changes in learned  
helplessness and imipramine. Behav. Neural Biol., 35, 344–353. 
Sherman, A.D., Sacquitne, J.L., Petty, F. (1982). Specifictiy of the learned helplessness  
model of depression. Pharmacol. Biochem. Behav., 16. 449–454. 
Takamori, K., Yoshida, S., & Okuyama, S. (2001). Repeated treatment with imipramine,  
fluvoxamine and tranylcypromine decreases the number of escape failures by  
activating  dopaminergic systems in a rat learned helplessness test. Life  
sciences, 69(16), 1919-1926. 
Uher, R., Mors, O., Hauser, J., Rietschel, M., Maier, W., Kozel, D., ... & Gray, J. M.  
 
 45 
(2011). Changes in body weight during pharmacological treatment of  
depression. International journal of neuropsychopharmacology, 14(3), 367-375. 
Vorhees, C. V., & Williams, M. T. (2006). Morris water maze: procedures for assessing  
spatial and related forms of learning and memory. Nature protocols, 1(2), 848. 
Warren, S. G., & Juraska, J. M. (1997). Spatial and nonspatial learning across the rat  
estrous cycle. Behavioral neuroscience, 111(2), 259.  
Wang, P. S., Simon, G., & Kessler, R. C. (2003). The economic burden of depression and  
the cost‐effectiveness of treatment. International journal of methods in  
psychiatric research, 12(1), 22-33. 
Williamson, P. C. (1989). Somatic therapies in psychiatry. (Williamson, 1989) 
Yan, H. C., Cao, X., Das, M., Zhu, X. H., & Gao, T. M. (2010). Behavioral animal  
models of depression. Neuroscience bulletin, 26(4), 327-337. 
Zajecka JM, Tummala R. Tricyclics: still solid performers for the savvy psychiatrist.  
Current Psychiatry 2002; 1(6):31–39.  
Zohar, J., Nutt, D. J., Kupfer, D. J., Moller, H. J., Yamawaki, S., Spedding, M., & Stahl,  
S. M. (2014). A proposal for an updated neuropsychopharmacological  










Non-normative Means for Sucrose and Water Consumption 
 
 
Non-normative Means for Light Aversion Operant Task Values 
 
 






Sucrose Total - Females


















Sucrose Total - Males


















H20 Total - Females

















H20 Total - Males

















Escapes - Female - Non-normative
































Escapes - Male - Non-normative































Omissions - Female - Non-normative
































Omissions - Male - Non-normative 






























Day 0 Day 22 Day 29 Day 36
Fluoxetine Female 8.11 5.89 6.67 7.89
Vehicle Female 8.89 7.78 7.56 9.22
Fluoxetine Male 9.56 6.56 6.67 7.00
Vehicle Male 7.90 8.30 7.40 7.60
Non-normative Escape Responses
 
Day 0 Day 22 Day 29 Day 36
Fluoxetine Female 8.44 11.00 10.33 8.67
Vehicle Female 8.00 9.33 9.67 8.22
Fluoxetine Male 7.22 10.22 10.44 9.44
Vehicle Male 9.20 8.90 11.30 9.20
Non-normative Omission Responses
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Non-normative Latency Averages - Female















Non-normative Latency Averages - Male














Total Resp - Female - Non-normative































Total Resp - Male - Non-normative


























Day 0 Day 22 Day 29 Day 36
Fluoxetine Female 3.33 2.56 4.67 4.67
Vehicle Female 7.44 9.67 10.78 11.89
Fluoxetine Male 6.00 3.56 3.67 3.89
Vehicle Male 4.10 4.40 3.50 4.30
Non-normative Premature Responses
 
Day 0 Day 22 Day 29 Day 36
Fluoxetine Female 22.12 23.17 23.70 22.22
Vehicle Female 21.00 22.15 18.73 20.66
Fluoxetine Male 21.27 23.88 23.66 23.89
Vehicle Male 20.50 21.33 22.42 21.86
Non-normative Latency Averages
 
Day 0 Day 22 Day 29 Day 36
Fluoxetine Female 11.44 8.56 11.33 12.33
Vehicle Female 16.44 16.89 18.33 21.11
Fluoxetine Male 15.56 10.33 10.67 11.11
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